HAP Trading’s Esperion Therapeutics ESPR Stock Holding History

HAP Trading’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,597	Closed	-$487K	–	1042
2018 Q2	$415K	Buy	+10,597	New	+$535K	0.02%	353

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HAP Trading's ESPR Position: Q3 2018 in Review

HAP Trading sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 10,597 shares — an estimated $487K sold.

HAP Trading first reported a position in ESPR in Q2 2018 and held it in 1 quarter. The position peaked at $415K in Q2 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

HAP Trading reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
HAP Trading sold 10,597 Esperion Therapeutics shares in Q3 2018, an estimated $487K.
HAP Trading first reported a position in Esperion Therapeutics in Q2 2018 and held it in 1 quarter.
HAP Trading's Esperion Therapeutics position peaked at $415K in Q2 2018.
155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on HAP Trading's 13F filing for Q3 2018, filed 9 Nov 2018.